Sublingual allergen-specific immunotherapy (AIT) is important option in the therapy of aero-allergen allergies. The first study evaluating the effectiveness and safety of this method appeared in 1986. Since then, several valuable clinical trials evaluating the efficacy and safety of sublingual AIT have been performed. Most of them was concerned on desensitization to popula allergens as grass pollen, birch and house dust mites. Allergen-specific immunotherapy with the use Staloral is effective and safe in children and adults. This opinion based on many scientific data including trials, meta analyses and real life studies. Staloral 300 has many features that predispose it to wide use in perennial or seasonal rhinoconjunctivitis with or without bronchial asthma. This is due to its formula and flexibility in the possible dosage for patients in every age group admitted to the AIT. This review presents current data on Staloral based on the literature and experience.